宫颈癌筛查人群对自取样尿液HPV检测的接受度及影响因素分析

doi:10.11904/j.issn.1002-3070.2025.05.008

实用肿瘤学杂志 ›› 2025, Vol. 39 ›› Issue (5): 412-417.doi: 10.11904/j.issn.1002-3070.2025.05.008

宫颈癌筛查人群对自取样尿液HPV检测的接受度及影响因素分析

李一凡¹, 秦川玉¹, 曾玺², 陆娅胶¹, 廖光东², 康乐妮³, 杨英¹, 周敏⁴, 郄明蓉², 杨春霞¹, 李静¹

1.四川大学华西公共卫生学院/四川大学华西第四医院(成都 610041);
2.四川大学华西第二医院妇科;
3.四川大学华西第二医院全国妇幼卫生监测办公室;
4.成都市双流区妇幼保健院妇幼健康科

收稿日期:2024-05-21 修回日期:2025-09-23 出版日期:2025-10-28 发布日期:2025-11-07
通讯作者: 李静,E-mail:lijingwcph@scu.edu.cn
作者简介:李一凡,女,(1999—),硕士,从事流行病与卫生统计学相关的研究。

Analysis of the acceptance and influencing factors of self-collection urine HPV testing in cervical cancer screening

LI Yifan¹, QIN Chuanyu¹, ZENG Xi², LU Yajiao¹, LIAO Guangdong², KANG Leni³, YANG Ying¹, ZHOU Min⁴, XI Mingrong², YANG Chunxia¹, LI Jing¹

1. West China School of Public Health and West China Fourth Hospital,Sichuan University,Chengdu 610041,China;
2. Department of Gynaecology,West China Second University Hospital,Sichuan University;
3. National Maternal and Child Health Monitoring Office,West China Second Hospital,Sichuan University;
4. Department of Maternal and Child Health,Chengdu Shuangliu District Maternal and Child Health Care Hospital

Received:2024-05-21 Revised:2025-09-23 Online:2025-10-28 Published:2025-11-07

摘要/Abstract

摘要： 目的探讨适龄女性对自取样尿液人乳头瘤病毒(human papilloma virus,HPV)检测用于宫颈癌筛查的接受度及影响因素,为在低资源地区推广该检测提供科学依据。方法 2022—2023年于四川省成都市双流区妇幼保健院开展以人群为基础的横断面研究,研究对象为21~69岁女性,采用自定义问卷对参与者进行一般情况和接受度调查。结果共纳入2 062名女性,平均年龄为51.58±9.34岁,1 501名(72.79%)女性认为尿液自取样非常容易。1 333名(64.65%)女性更愿意接受医生取样作为宫颈癌筛查取样方法,仅729名(35.35%)女性更愿意接受自取样尿液HPV检测。年龄、学历水平、家庭年收入、是否知道HPV、是否接种过HPV疫苗、是否对医生取样过程有羞耻感均与筛查女性对自取样尿液HPV检测的接受度有关(P＜0.001)。多因素logistic回归分析结果表明,年龄越大(OR=0.965,95% CI:0.951~0.979)、不了解HPV(OR=0.760,95% CI:0.602~0.961)的筛查女性更难接受自取样尿液HPV检测,而学历为初中(OR=1.330,95% CI:1.053~1.682)、高中及以上(OR=1.990,95% CI:1.401~2.827)、对医生取样过程有羞耻感(OR=2.314,95% CI:1.706~3.142)的筛查女性更容易接受自取样尿液HPV检测。结论多数女性认为自取样尿液HPV检测非常容易,但是相较于医生取样,仅部分女性会选择自取样尿液HPV检测,对于高年龄者和低教育水平人群应进行重点健康教育干预。

关键词: 尿液人乳头瘤病毒检测, 宫颈癌筛查人群, 接受度

Abstract: Objective The aim of this study was to explore the acceptance and influencing factors of self-collected urine samples for human papillomavirus(HPV)testing in cervical cancer screening among eligible women,and to provide scientific evidence for promoting this testing in low resource areas. Methods A population-based cross-sectional study was conducted from 2022 to 2023 at the Maternal and Child Health Hospital in Shuangliu district,Chengdu City Sichuan Province.The study subjects were women aged 21 to 69 years old,and a customized questionnaire was used to conduct general information and acceptance surveys on the participants. Results A total of 2,062 women were included,with an average age of 51.58±9.34 years.Among them,1,501(72.79%)women believed that self-sampling urine was very easy.However,although 1,333(64.65%)women were still willing to accept doctor sampling as a cervical cancer screening method,only 729(35.35%)were more willing to accept self-sampling urine HPV testing.Age,educational level,annual household income,awareness of HPV,HPV vaccination status,and a sense of shame about the doctor's sampling process were all associated with the acceptance of self-collected urine HPV testing among women undergoing cervical cancer screening(P＜0.001).The results of multivariate logistic regression analysis indicated that older women(OR=0.965,95% CI:0.951-0.979)and those who were not familiar with HPV(OR=0.760,95% CI:0.602-0.961)were more likely to undergo self sampling urine HPV testing,while those with junior high school education(OR=1.330,95% CI:1.053-1.682),high school education or above(OR=1.990,95% CI:1.401-2.827),and a sense of shame towards the doctor's sampling process(OR=2.314,95% CI:1.706-3.142)were more likely to undergo self sampling urine for HPV testing. Conclusions Most women believe that self sampling urine for HPV testing is very easy,but compared to doctor sampling,only some women choose to self sample urine for HPV testing.Key health education interventions should be carried out for older and lower educated populations to promote acceptance of urine HPV testing.

Key words: urine human papilloma virus testing, cervical cancer screening population, acceptance

中图分类号:

R737.33

李一凡, 秦川玉, 曾玺, 陆娅胶, 廖光东, 康乐妮, 杨英, 周敏, 郄明蓉, 杨春霞, 李静. 宫颈癌筛查人群对自取样尿液HPV检测的接受度及影响因素分析[J]. 实用肿瘤学杂志, 2025, 39(5): 412-417.

LI Yifan, QIN Chuanyu, ZENG Xi, LU Yajiao, LIAO Guangdong, KANG Leni, YANG Ying, ZHOU Min, XI Mingrong, YANG Chunxia, LI Jing. Analysis of the acceptance and influencing factors of self-collection urine HPV testing in cervical cancer screening[J]. Journal of Practical Oncology, 2025, 39(5): 412-417.

参考文献

1 World Health Organzation.Cervical cancer[EB/OL].(2022-02-22)[2023-12-12].https://www.who.int/news-room/fact-sheets/detail/cervical-cancer.
2 Ault KA.Epidemiology and natural history of human papillomavirus infections in the female genital tract[J].Infect Dis Obstet Gynecol,2006,2006:40470.
3 World Health Organization.World Health Assembly adopts global strategy to accelerate cervical cancer elimination[EB/OL].(2020-08-19)[2023-12-1].https://www.who.int/news/item/19-08-2020-world-health-assembly-adopts-global-strategy-to-accelerate-cervical-cancer-elimination.
4 妇幼健康司.卫生部、全国妇联关于印发《农村妇女“两癌”检查项目管理方案》的通知[EB/OL].(2009-06-30)[2024-01-17].https://www.nhc.gov.cn/wjw/gfxwj/200906/e1bed16a6c9b4a07b00389ab9ab202a8.shtml.
5 Zhang M,Zhong Y,Wang L,et al.Cervical cancer screening coverage - China,2018-2019[J].China CDC Wkly,2022,4(48):1077-1082.
6 World Health Organzation.A cervical cancer-free future:First-ever global commitment to eliminate a cancer [EB/OL].(2020-11-17)[2024-01-17].https://www.who.int/news/item/17-11-2020-a-cervical-cancer-free-future-first-ever-global-commitment-to-eliminate-a-cancer.
7 Yang H,Li SP,Chen Q,et al.Barriers to cervical cancer screening among rural women in eastern China:a qualitative study[J].BMJ Open,2019,9(3):e026413.
8 Nyabigambo A,Mayega RW,Mendoza H,et al.The preference of women living with HIV for the HPV self-sampling of urine at a rural HIV clinic in Uganda[J].S Afr J Infect Dis,2022,37(1):414.
9 Xu H,Yu Y,George W,et al.Comparison of the performance of paired urine and cervical samples for cervical cancer screening in screening population[J].J Med Virol,2020,92(2):234-240.
10 Xu HF,Zhao XL,Zhao S,et al.Clinical performance of a newly developed domestic urine-based HPV test for cervical cancer screening in China[J].J Med Virol,2023,95(4):e28705.
11 Cho HW,Shim SR,Lee JK,et al.Accuracy of human papillomavirus tests on self-collected urine versus clinician-collected samples for the detection of cervical precancer:a systematic review and meta-analysis[J].J Gynecol Oncol,2022,33(1):e4.
12 Kaoma M,Olayemi O,Mwaba MH,et al.Utilizing first void urine for high-risk HPV testing for cervical cancer screening in HIV-positive women in Katete,Zambia[J].BMC Womens Health,2023,23(1):62.
13 Van Keer S,Tjalma WA,Pattyn J,et al.Human papillomavirus genotype and viral load agreement between paired first-void urine and clinician-collected cervical samples[J].Eur J Clin Microbiol Infect Dis,2018,37(5):859-869.
14 周艳秋,胡启彩,杨智敬,等.深圳女性人乳头瘤病毒自取样宫颈癌筛查认知与影响因素调查[J].中华现代护理杂志,2016(17):2426-2430.
15 赵昀,廖琪,米鑫,等.自取样HPV检测技术在子宫颈癌筛查人群中的接受状况调查[J].中华妇产科杂志,2019(5):312-317.
16 Le D,Coriolan Ciceron A,Jeon MJ,et al.Cervical cancer prevention and high-risk HPV self-sampling awareness and acceptability among women living with HIV:a qualitative investigation from the patients' and providers' perspectives[J].Curr Oncol,2022,29(2):516-533.
17 Vega Crespo B,Neira VA,Ortíz SJ,et al.Evaluation of urine and vaginal self-sampling versus clinician-based sampling for cervical cancer screening:a field comparison of the acceptability of three sampling tests in a rural community of cuenca,ecuador[J].Healthcare(Basel),2022,10(9):1614.
18 Shin HY,Lee B,Hwang SH,et al.Evaluation of satisfaction with three different cervical cancer screening modalities:clinician-collected Pap test vs.HPV test by self-sampling vs.HPV test by urine sampling[J].J Gynecol Oncol,2019,30(5):e76.
19 徐慧芳,乔友林.尿液HPV检测的研究进展[J].中国肿瘤,2019,28(09):705-709.
20 Hoffmann R,Lutz SU.The health knowledge mechanism:evidence on the link between education and health lifestyle in the Philippines[J].Eur J Health Econ,2019,20(1):27-43.
21 Sy AU,Hernandez BY,Tareg A,et al.Acceptability and feasibility of a community based participatory research project comparing cytology and urine HPV DNA testing for cervical cancer screening in Yap,Federated States of Micronesia[J].Cancer Epidemiol,2017,50(Pt B):283-288.

[1]	王孟菲, 许波群. 局部晚期宫颈癌免疫治疗进展[J]. 实用肿瘤学杂志, 2025, 39(2): 157-161.
[2]	张华, 努尔比亚·依比布拉, 路鹏霏, 贾春丽, 裴轩萱, 包永星. CXCL8对宫颈癌细胞紫杉醇敏感性的影响及机制研究[J]. 实用肿瘤学杂志, 2025, 39(1): 13-20.
[3]	陈茂森, 文洪梅, 石青萍, 邵英, 唐娴, 任思颖, 陈杨. 2020年云南省肿瘤登记地区宫颈癌发病和死亡情况及2012—2020年趋势分析[J]. 实用肿瘤学杂志, 2024, 38(6): 355-360.
[4]	周建云, 储巧香, 陆月梅, 朱静, 丁其培. lncRNA GAS5对宫颈癌细胞增殖、侵袭能力及PTEN/Akt/mTOR信号通路的影响[J]. 实用肿瘤学杂志, 2024, 38(2): 96-103.
[5]	韩霞, 丁高恒, 杨菁, 刘玉琴, 陈岚, 宋国贤. 2019年甘肃省肿瘤登记地区子宫体癌流行特征及2010—2019年变化趋势分析[J]. 实用肿瘤学杂志, 2024, 38(1): 7-12.
[6]	李书桢, 蔡志福, 容雁, 庞业滨, 罗冬妮, 高琨. 肿瘤体积在宫颈癌近距离治疗中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(1): 63-67.
[7]	徐慧芳, 刘茵, 赵冬梅, 罗艳林, 陈佩佩, 郭珍, 贾漫漫, 郑黎阳, 张璐瑶, 李梦洁, 张韶凯. 新型国产杂交捕获HPV检测技术在ASC-US人群分流中的应用效果评价[J]. 实用肿瘤学杂志, 2022, 36(2): 133-136.
[8]	张艺艺, 李奇, 刘旭, 王亚楠, 邹沅杰, 周慧慧, 徐春燕, 苏升琦, 葛鑫, 王铜. 宫颈癌患者五年生存及影响因素分析[J]. 实用肿瘤学杂志, 2022, 36(1): 7-13.
[9]	王榆平, 思美丽, 孙小霞, 郭玉琳. HPIP在子宫内膜癌中高表达及其在生存预后分析中的意义[J]. 实用肿瘤学杂志, 2022, 36(1): 44-48.
[10]	马莉, 郭思宏, 朱博熠, 陈杰. 宫颈冷刀锥切术联合抗HPV生物蛋白敷料治疗HSIL合并高危型HPV感染的临床效果研究[J]. 实用肿瘤学杂志, 2021, 35(5): 426-430.
[11]	王亮亮, 丁高恒, 陈莉莉, 吴建军, 刘玉琴, 魏兴民. 2009—2015年甘肃省肿瘤登记地区胰腺癌流行特征及变化趋势分析[J]. 实用肿瘤学杂志, 2021, 35(3): 200-206.
[12]	郭伟, 朱奕潼, 丁高恒, 朱公建, 刘玉琴, 吴建军. 2009—2015年甘肃省肿瘤登记地区子宫体癌发病与死亡特征分析[J]. 实用肿瘤学杂志, 2021, 35(3): 207-211.
[13]	姚丽萍, 王宏宗, 丁高恒, 刘玉琴. 2009—2015年甘肃省肿瘤登记地区宫颈癌流行特征及变化趋势分析[J]. 实用肿瘤学杂志, 2021, 35(3): 224-230.
[14]	黎敏, 冉立, 常建英. 影像学技术在图像引导宫颈癌近距离放射治疗中的应用[J]. 实用肿瘤学杂志, 2021, 35(3): 263-267.
[15]	秦伟, 何义富, 常娜, 钱立庭, 黄大兵, 崔亚云. 局部晚期宫颈癌放射治疗对直肠功能影响的研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 170-173.

宫颈癌筛查人群对自取样尿液HPV检测的接受度及影响因素分析

Analysis of the acceptance and influencing factors of self-collection urine HPV testing in cervical cancer screening

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价